Mitralign adds another $8 million to its coffers a few months after closing enrollment on a clinical trial of its mitral valve repair device.
Mitralign added more than $8 million to its coffers in an equity funding round, after closing enrollment of a clinical trial for its namesake mitral valve repair device in April.
Help employers find you! Check out all the jobs and post your resume.
